Related Experiment Video

Updated: Jun 21, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists

K B Hansen1, F K Knop, J J Holst

  • 1Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej, Copenhagen, Denmark. Kbaggehansen@dadlnet.dk

International Journal of Clinical Practice
|July 24, 2009
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists offer a promising new approach for type 2 diabetes management. These agents improve glucose control, aid weight loss, and may protect pancreatic beta-cell function, with a low risk of hypoglycemia.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes management remains challenging, with existing drugs often failing to achieve glycemic goals.
  • Current treatments do not prevent the decline of pancreatic beta-cell function and can cause side effects like hypoglycemia and weight gain.
  • The incretin system presents a significant therapeutic target for novel diabetes treatments.

Purpose of the Study:

  • To review the available data on Glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes.
  • To discuss the efficacy and safety of exenatide and liraglutide.

Main Methods:

  • Review of preclinical and clinical data on GLP-1 receptor agonists.
  • Comparative discussion of exenatide and liraglutide.

Main Results:

  • GLP-1 receptor agonists enhance glucose homeostasis through multiple mechanisms.
  • These mechanisms include increased insulin secretion, decreased glucagon secretion, and reduced gastric emptying, appetite, and body weight.
  • Preclinical data suggest potential preservation of beta-cell mass and function, with low hypoglycemia incidence and beneficial effects on cardiovascular risk factors.

Conclusions:

  • GLP-1 receptor agonists represent a novel therapeutic class for type 2 diabetes.
  • Exenatide and liraglutide show promise in improving glycemic control, promoting weight loss, and potentially preserving beta-cell function.
  • These agents offer a favorable safety profile with low hypoglycemia risk and potential cardiovascular benefits.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...